Clinical trials: PD
Parkinson's Disease (PD)
Coordinated Reset Deep Brain Stimulation
The study will explore the viability of an alternative/novel programming strategy in Deep Brain Stimulation (DBS) for patients with Parkinson's Disease (PD).
- Trial name
- RESET-DBS (NCT03732898)
- Testing
- Novel Programming (nDBS), Conventional Programming (cDBS)
- Where
- 2 sites in Germany
- Volunteers
- 15 people
- Sponsor
- Boston Scientific Corporation
Sickle Cell Disease (SCD)
Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC)
The purpose of the CSEG101A2202 study was to characterize the Pharmacokinetic (PK) and Pharmacodynamic (PD) of SEG101/crizanlizumab and to evaluate the safety and efficacy of SEG101/crizanlizumab in sickle cell disease (SCD)…
- Trial name
- NCT03264989
- Testing
- crizanlizumab
- Where
- 12 sites in United States
- Volunteers
- 57 people
- Sponsor
- Novartis Pharmaceuticals
Muscular Atrophy, Spinal
Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy
Open-label, multi-center clinical study is to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamics (PD), and efficacy of Risdiplam (RO7034067) in infants with Type 1 spinal muscular atrophy (SMA).
- Trial name
- FIREFISH (NCT02913482)
- Testing
- Risdiplam
- Where
- 32 sites in United States, Belgium and 14 more
- Volunteers
- 62 people
- Sponsor
- Hoffmann-La Roche
Melanoma
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
This 2-part study will evaluate the safety and efficacy of pembrolizumab (MK-3475) compared to placebo in participants with surgically resected high-risk Stage II melanoma.
- Trial name
- NCT03553836
- Testing
- Pembrolizumab
- Where
- 159 sites in United States, Australia and 14 more
- Volunteers
- 976 people
- Sponsor
- Merck Sharp & Dohme LLC
Tooth, Impacted, Tooth Diseases
Ibuprofen Liquid Capsules 2 x 200 mg Efficacy and PK/PD Study in Surgical Removal of Impacted Third Molars
This is a single centre, three-arm randomised, double-blind, double-dummy, parallel group, single-dose, active and placebo-controlled efficacy and pharmacokinetics/ pharmacodynamics study to evaluate the efficacy and safety of 2…
- Conditions
- Tooth, Impacted, Tooth Diseases, Stomatognathic Diseases
- Trial name
- NCT05484401
- Testing
- Ibuprofen 200Mg Oral Cap, Ibuprofen 200Mg Oral Tablet
- Where
- United States
- Volunteers
- 294 people
- Sponsor
- Reckitt Benckiser Healthcare (UK) Limited
Parkinson's Disease (PD)
An Observational Study of Subcutaneous Infusion of ABBV-951 to Assess Change in Disease Activity and Adverse Events In Adult Japanese Participants With Advanced Parkinson's Disease
Parkinson's disease (PD) is a neurological condition, which affects the brain. Some symptoms of PD are tremors, stiffness, and slowness of movement.
- Trial name
- NCT05916157
- Where
- 17 sites in Japan
- Volunteers
- 250 people
- Sponsor
- AbbVie
Thermal Burn
Evaluation of the Effectiveness of PermeaDerm® (PD) as Compared to Mepilex Ag®
A total of 68 adult and pediatric patients who suffer from at least one discrete partial thickness thermal burn wound (Grade II) will be recruited. Subjects will be randomized (1:1) to either PermeaDerm® or Mepilex Ag®.
- Trial name
- NCT05084183
- Testing
- PermeaDerm®, Mepilex Ag
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Stedical Scientific, Inc.
Ewing Family of Tumors, Rhabdomyosarcoma
PK/PD of XM22 in Children With Ewing Family of Tumors or Rhabdomyosarcoma
This is a Phase I, open label study aimed at assessing the pharmacokinetics, pharmacodynamics, the efficacy, safety, and tolerability of a single injection of XM22 in children with Ewing family of tumors or rhabdomyosarcoma…
- Trial name
- NCT01585649
- Testing
- Lipegfilgrastim
- Where
- 18 sites in Bulgaria, Czechia and 4 more
- Volunteers
- 21 people
- Sponsor
- Merckle GmbH
Renal Insufficiency / Therapy
PD Catheter Data Collection
Peritoneal Dialysis (PD) is a Renal Replacement Therapy for patients with renal insufficiency that has been used more frequently in recent years.
- Trial name
- Catheter (NCT07156123)
- Where
- 2 sites in Germany
- Volunteers
- 300 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
Hemophilia A, Hemophilia B
A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150
Haemophilia is a disorder, usually genetic, affecting mostly male individuals, in which one of the proteins needed to form blood clots (FVIII) is missing or not present in sufficient levels.
- Trial name
- NCT01625390
- Testing
- BAY86-6150, eptacog alfa [activated]
- Where
- 61 sites in United States, Australia and 27 more
- Volunteers
- 10 people
- Sponsor
- Bayer
Squamous Cell Carcinoma of the Head and Neck
SUPREME-HN A Retrospective Cohort Study of PD-L1 in Recurrent and Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)
This is a retrospective international, multi-center, non-interventional cohort study based on use of data derived from established medical records and secondary analysis of archival tumor samples.
- Trial name
- SUPREME-HN (NCT02543476)
- Where
- 18 sites in United States, Germany and 5 more
- Volunteers
- 412 people
- Sponsor
- AstraZeneca
Asthma
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma
The purpose of this study is to characterize the bronchodilator effect, systemic exposure and safety/tolerability of two different doses of inhaled glycopyrronium, when compared to placebo.
- Trial name
- NCT05222529
- Testing
- Glycopyrronium bromide 25ug, Glycopyrronium bromide 12.5ug
- Where
- 23 sites in Bulgaria, Colombia and 6 more
- Volunteers
- 42 people
- Sponsor
- Novartis Pharmaceuticals
Parkinson Disease
Compassionate Use for BIA 28-6156 in Patients With Parkinson's Disease (PD) Who Have a Pathogenic Variant in the GBA1 Gene (GBA-PD) and Completed the ACTIVATE Study
This Program is designed to provide continued access BIA 28-6156, free and compassionately for an eligible patient previously enrolled in the BIA 28-6156-201 (ACTIVATE) clinical study and that had completed the study.
- Trial name
- NCT07522606
- Testing
- BIA 28-6156
- Where
- 36 sites in United States, Italy and 3 more
- Sponsor
- Bial R&D Investments, S.A.
Classic Galactosemia
Clinical Benefit, Safety, PK and PD Study of AT-007 in Pediatric Subjects With Classic Galactosemia
This study is designed to assess the clinical benefit as well as the safety, pharmacokinetics (PK), and pharmacodynamics (PD) (reduction of galactitol levels) of AT-007 in pediatric subjects with Classic Galactosemia (CG).
- Trial name
- NCT04902781
- Testing
- AT-007
- Where
- 3 sites in United States
- Volunteers
- 47 people
- Sponsor
- Applied Therapeutics, Inc.
Infections, Streptococcal
Post Marketing Surveillance of Synflorix Vaccine Safety Among Infants in Korea
The purpose of this study is to collect safety information following routine vaccination with Synflorix™ among infants in Korea.
- Trial name
- NCT01248988
- Testing
- Synflorix™ Data collection
- Where
- South Korea
- Volunteers
- 622 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Generalized Myasthenia Gravis, gMG
PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
The primary objective of this study is to assess the pharmacokinetics and pharmacodynamics of gefurulimab in pediatric participants with AChR+ gMG for the duration of the study.
- Trial name
- NCT06607627
- Testing
- Gefurulimab
- Where
- 13 sites in United States, Brazil and 3 more
- Volunteers
- 12 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Hypoglycemia, Type 1 Diabetes
A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1D
This research study will investigate whether dasiglucagon as a rescue therapy for participants under 6 years of age works and is safe to use.
- Trial name
- NCT05378672
- Testing
- Dasiglucagon
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Zealand Pharma
Pediatric Growth Hormone Deficiency
Versartis Trial in Children to Assess Long-Acting Growth Hormone
This is a Phase 1b/2a study of VRS-317 (long-acting growth hormone) in pediatric patients with growth hormone deficiency. During Phase 1b, pediatric patients each will receive a single subcutaneous injection of VRS-317.
- Trial name
- VERTICAL (NCT01718041)
- Testing
- Experimental: VRS-317
- Where
- 23 sites in United States
- Volunteers
- 64 people
- Sponsor
- Versartis Inc.
Acute Myocardial Infarction
Metoprolol in Acute Myocardial Infarction. A PK/PD Study
The objective of the study was to compare treatment with two different oral formulations of metoprolol, metoprolol immediate release (IR) and metoprolol extended release (CR/XL) in patients with acute myocardial infarction…
- Trial name
- NCT01523054
- Testing
- Metoprolol- Toprol XL, Metoprolol- Lopressor
- Volunteers
- 27 people
- Sponsor
- AstraZeneca
Asthma
Inhaled Fluticasone Furoate/Vilanterol Safety and Tolerability, PK and PD Study
This study will investigate the safety and tolerability, pharmacokinetics, and pharmacodynamics of fluticasone furoate/vilanterol (FF/VI) 100/25mcg administered using the novel dry powder inhaler in children aged 5 to 11 years…
- Trial name
- NCT01453023
- Testing
- Fluticasone Furoate, Fluticasone Furoate/Vilanterol
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- GlaxoSmithKline